InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System

June 24, 2020

Read More »

InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation

June 19, 2020

Read More »

InMed Releases CBN Preclinical Results in Glaucoma

May 27, 2020

Read More »

InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family

May 19, 2020

Read More »

InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

May 14, 2020

Read More »

InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

May 14, 2020

Read More »

InMed Files PCT Patent Application for Neuroprotection in Glaucoma

May 12, 2020

Read More »

Notice of Telephone Scam Impersonating InMed

May 8, 2020

Read More »

InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020

May 8, 2020

Read More »

InMed to Present at Canaccord Genuity’s 4th Annual Cannabis Conference

May 7, 2020

Read More »

InMed and Almac Group Developing Improved Cannabinoid Production Methods

May 5, 2020

Read More »

InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755

April 30, 2020

Read More »

InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

April 1, 2020

Read More »

InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial

March 24, 2020

Read More »

InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak

March 20, 2020

Read More »

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

March 10, 2020

Read More »

InMed Pharmaceuticals Reports Second Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

February 14, 2020

Read More »

InMed Pharmaceuticals to Report Second Quarter Fiscal 2020 Financial Results and Business Update on February 14, 2020

February 7, 2020

Read More »

InMed Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview

January 21, 2020

Read More »

InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials

January 20, 2020

Read More »